Navigation Links
Pharmos Corporation Reports 2009 Third Quarter Results
Date:11/12/2009

urred during the first nine months of 2009 in connection with the trial, comprising CRO-related activities. All patients in the trial completed treatment in July of 2009 and top line clinical data was released in September 2009. The results of the Dextofisopam Phase 2b clinical trial were announced on September 14, 2009. While the trial did not meet the primary endpoints for any of the three drug dose arms, drug activity was clearly evident at the 200 mg. dose level. On October 21, 2009 the Company announced that it had engaged Cowen and Company as advisors to assist with accelerating a partnership arrangement for Dextofisopam.

In process research and development costs which were related to the Vela milestone increased by $1,180,000 from $0 in 2008 to $1,180,000 in 2009. On April 9, 2009 the last patients were enrolled in the Phase 2b trial thus triggering the following milestone: $1 million cash + 2 million shares of Pharmos common stock: Final patient enrolled in Phase 2b trial. The expense of the milestone of $1,180,000 has been reflected in the 1Q 2009 results. The payment of the cash portion of the milestone has been deferred under an amendment to the acquisition agreement. Under the terms of the Vela acquisition agreement as amended, the 2 million shares will be issued on November 2, 2009. Since the trial results were not successful, no other milestones have been achieved.

General and administrative expenses for the first nine months of 2009 decreased by $585,882, or 35%, from $1,687,747 in 2008 to $1,101,865 in 2009. The decline reflects decreases in virtually every general and administrative expense category. The primary reductions include a $359,000 reduction in payroll, a $100,000 reduction in miscellaneous expenses, a $123,000 reduction in consultant and professional fees and a reduction in various other expenses of $75,000. This is offset in part, by increases of $36,000 in investor relations and $34,000 of miscellaneous expenses.
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmos Issues Business Update on Dextofisopam Trial and Financing
2. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
3. MedCath Corporation Reports Fourth Quarter Earnings
4. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
5. Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
8. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
9. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
10. MedCath Corporation to Hold Conference Call on Fourth Quarter Results
11. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is proud ... in San Diego, California’s Gaslamp Quarter Plaza for five years this September. , ... monitor the area for any suspicious activity. These cameras are in place to ...
(Date:7/30/2015)... ... July 30, 2015 , ... " DevExpress ” ... a look at small, medium, and large businesses making an impact in their ... business review and shared with viewers how DevExpress has provided software development tools ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Beryl ... Scholar Program. In partnership with Patient Experience Institute, these offerings reinforce the commitment ... the front lines and throughout the experience movement, and provide information and research ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... today that the latest issue of Inclusive™ magazine, its multimedia publication focused on ... digital edition of the new issue, Volume 6, Issue 2, as well as ...
(Date:7/30/2015)... ... July 30, 2015 , ... Between 2012 and 2014 HIV ... Health News Florida on June 17th. Those untreated heroin use disorders share their ... the spread of dirty needles throughout the community. Ultimately Florida’s HIV infection rates have ...
Breaking Medicine News(10 mins):Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3
... The naturally high levels of leptin in diabetic patients ... treat heart blockages, but using a chemical that differs ... counteract this effect. , The work by researchers at ... diabetics who get stents, they say. Though drug-eluting stents ...
... Pheromone,Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the ... with the U.S. Patent and,Trademark Office for the use ... in sea coral, which has significant emotional impacts,on both ... well-being and social attraction. , ...
... United Health Foundation announced its commitment to American Indian ... Indian Country by donating $45,000 for nine $5,000 scholarships ... support of Arizona students pursuing careers in the health ... scholarship recipients were chosen based on their academic achievement, ...
... SACRAMENTO, Calif., Dec. 17 Sutter Health has announced,the ... general,counsel. She will assume her new role January 5, ... , Formerly senior ... Eisenbeis, LLP (HRDE) for the past two decades, DiBenedetto,served ...
... Hospital have answered a central question in cancer biology: ... Stem cells are immature cells that can renew themselves ... the range of body tissues. In recent years, researchers ... forms of stem cells. , Like a brand-name ...
... Combines ZEISS,s Precision Progressive Lenses and Transitions® Lenses to Produce Optimal ... ... 17, 2008 -- Two of the most distinguished names in the ... leading-edge eyewear., , ,Carl Zeiss Vision, a leader for 160 years ...
Cached Medicine News:Health News:HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral 2Health News:United Health Foundation Provides $45,000 for Scholarships to the American Indian College Fund for Arizona Healthcare Students 2Health News:United Health Foundation Provides $45,000 for Scholarships to the American Indian College Fund for Arizona Healthcare Students 3Health News:Sutter Health Welcomes New General Counsel 2Health News:Molecular marker identifies normal stem cells as intestinal tumor source 2Health News:Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers 2
... up to 10 inches/ 25 cm thinner than other ... Allegra X-22 Series is the space-saving multipurpose solution for ... / 46 cm wide • 11 Rotor Library • ... ways to Spin 1.5 mL & PCR+ Tubes: ...
... is up to 10 inches/ 25 cm thinner than ... the Allegra X-22 Series is the space-saving multipurpose solution ... inches / 46 cm wide • 11 Rotor Library ... different ways to Spin 1.5 mL & PCR+ Tubes: ...
... centrifuges offer high-volume versatility along with a ... them ideal for a wide variety of ... Four- or six-place sealed swinging bucket rotor, ... offered , Lare capacity (4 x 750 ...
... Multipurpose high performance centrifuge designed to accommodate ... devices is refrigerated for heat labile samples. ... include refrigerated capability with automatic quick cooling ... < 7 min, no maintenance brushless motor, ...
Medicine Products: